Hepatocellular carcinoma tumour markers: Current role and expectations

Research output: Contribution to journalReview articlepeer-review

88 Scopus citations


Tumour markers could be helpful along the continuum of care for patients with hepatocellular carcinoma; however, there is insufficient data for routine use of most current biomarkers in clinical practice. Therefore, the backbone of early detection, diagnosis and treatment response for hepatocellular carcinoma remains imaging-based. Alpha fetoprotein is the best studied of all biomarkers and may be of benefit for early detection when used in combination with ultrasound. Several other biomarkers, including AFP-L3, DCP, osteopontin, and GP73, are also being evaluated for early detection of hepatocellular carcinoma in phase III biomarker studies. Serum and tissue-based biomarkers and genomics may aid in HCC diagnosis, prognosis, and treatment selection; however, further studies are needed to better characterize their accuracy and potential role in clinical practice.

Original languageEnglish (US)
Pages (from-to)843-853
Number of pages11
JournalBest Practice and Research: Clinical Gastroenterology
Issue number5
StatePublished - Jan 1 2014


  • Alpha fetoprotein
  • Early detection
  • Hepatocellular carcinoma
  • Tumour markers

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Hepatocellular carcinoma tumour markers: Current role and expectations'. Together they form a unique fingerprint.

Cite this